An open-label, single-center and single-arm clinical study for infusion of anti-CD20 CAR-T cells for patients with relapsed or refractory B-cell malignancies
Latest Information Update: 01 Jul 2019
At a glance
- Drugs Anti-CD20 chimeric antigen receptor T-cell therapy-Wuhan BioRaid Biotechnology (Primary)
- Indications B-cell leukaemia; B-cell lymphoma
- Focus Adverse reactions
Most Recent Events
- 01 Jul 2019 New trial record